The researchers found that adding 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival and that the risk: benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab. Efficacy was similar, and there were fewer acute toxic effects and lower risks of cardiotoxicity and leukemia.
